Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Int Immunopharmacol ; 8(13-14): 1715-20, 2008 Dec 20.
Article in English | MEDLINE | ID: mdl-18708162

ABSTRACT

The shift to the production of a Th1 cytokine profile during an intracellular infection has been shown to depend on antigen presenting cells-derived IL-12 and T-cell-derived IFN-gamma production. IL-18 facilitates Th1 priming in synergy with IL-12 through the stimulation of IFN-gamma production by T cells, B cells, NK cells, macrophages and DCs. A low level of IFN-gamma production in PBMC cultures from lepromatous leprosy patients (LL) has been previously reported by several groups. We evaluated the synthesis of this cytokine after exogenous addition of recombinant IL-12 and IL-18 (IL12/IL18) in order to induce recovery of the IFN-gamma levels with Mycobacterium leprae antigenic stimulation. The aim of this study was to investigate if exogenous addition of IL12/IL18 to PBMC cell cultures in the presence of M. leprae antigens could induce recovery of IFN-gamma levels. We found that IFN-gamma levels in PBMCs cultured from LL patients were reestablished after exogenous addition of exogenous IL12/IL18 and we also observed a diminished IL-18R expression. Although the molecular mechanisms of IL12/IL18 synergy have not been clearly elucidated, we assume that recombinant cytokines can activate several transcription factors that induce IFN-gamma synthesis.


Subject(s)
Interferon-gamma/drug effects , Leprosy, Lepromatous/immunology , Leukocytes, Mononuclear/drug effects , Adjuvants, Immunologic/pharmacology , Adult , Aged , Antigens, CD/drug effects , Antigens, CD/immunology , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/drug effects , Antigens, Differentiation, T-Lymphocyte/immunology , Antigens, Differentiation, T-Lymphocyte/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Drug Synergism , Female , Humans , Interferon-gamma/biosynthesis , Interleukin-12/pharmacology , Interleukin-18/pharmacology , Interleukin-18 Receptor alpha Subunit/drug effects , Interleukin-18 Receptor alpha Subunit/immunology , Interleukin-18 Receptor alpha Subunit/metabolism , Lectins, C-Type , Leprosy, Lepromatous/microbiology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/microbiology , Male , Middle Aged , Mitogens/pharmacology , Mycobacterium leprae/immunology , Phytohemagglutinins/pharmacology , Recombinant Proteins/pharmacology
2.
Allergy Asthma Proc ; 24(1): 27-33, 2003.
Article in English | MEDLINE | ID: mdl-12635575

ABSTRACT

In this study we assessed, by flow cytometry, the effect of interleukin 2 (IL-2) on the oxidative burst of normodense eosinophils (Eos's) isolated from 15 patients with moderately severe extrinsic asthma and 17 controls. We found that IL-2 significantly induced peroxide (H2O2) production in normodense Eos's from patients with asthma on a time kinetics study. This rise was higher in patients with immunoglobulin E levels > 180 IU/mL versus normal immunoglobulin E values. The effect of IL-2 was partially blocked by using anti-Tac antibody. In contrast, IL-2 decreased H2O2 production in normodense Eos's from controls. Cell surface expression of CD25, CD122, CD132, and CD69 were also determined and no statistical differences were found between both groups. In conclusion, IL-2 is able to increase H2O2 production by normodense Eos's isolated from patients with asthma and it may contribute to bronchial epithelium damage and chronic inflammation.


Subject(s)
Asthma/blood , Eosinophils/drug effects , Eosinophils/metabolism , Interleukin-2/metabolism , Interleukin-2/pharmacology , Peroxides/metabolism , Adolescent , Adult , Antigens, CD/biosynthesis , Antigens, CD/drug effects , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Antigens, Differentiation, T-Lymphocyte/drug effects , Antigens, Surface/biosynthesis , Antigens, Surface/drug effects , Asthma/physiopathology , Biomarkers/blood , Carcinogens/pharmacology , Cell Survival/drug effects , Cell Survival/physiology , Coloring Agents , Female , Flow Cytometry , Humans , Immunoglobulin E/blood , Lectins, C-Type , Male , Peroxides/blood , Receptors, IgG/biosynthesis , Receptors, IgG/drug effects , Respiratory Burst/drug effects , Respiratory Burst/physiology , Stimulation, Chemical , Tetradecanoylphorbol Acetate/pharmacology , Time Factors , Trypan Blue , Venezuela
3.
J Leukoc Biol ; 70(2): 297-305, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11493623

ABSTRACT

This study evaluates the effects of insulin-like growth factor (IGF)-1 receptor (IGF-1R) down-regulation in stimulated T lymphocytes by investigating the expression of early activation proteins CD69, CD25, and interleukin (IL)-2. We found that IGF-1 does not modify CD69 expression but increases transcription and protein synthesis of CD25 and IL-2. The lowest level of IGF-1R detected after 15 min of activation suggested that the effects of IGF-1 occur at the initiation of cell activation. The activation of IGF-1R was confirmed by IGF-1R phosphorylation and increased phosphorylation of microtubule-associated protein kinase. We also detected the alternative IGF-1 transcripts Ea, with paracrine/autocrine regulation, and Eb, with endocrine regulation, in Jurkat cells and in quiescent T lymphocytes, and we detected IGF-1 protein in the culture medium after stimulation. These data suggest that the proliferative effects of IGF-1 on T lymphocytes include both autocrine/paracrine and endocrine processes.


Subject(s)
Immediate-Early Proteins/drug effects , Insulin-Like Growth Factor I/pharmacology , Lymphocyte Activation , T-Lymphocytes/drug effects , Antigens, CD/drug effects , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/drug effects , Antigens, Differentiation, T-Lymphocyte/metabolism , Down-Regulation , Humans , Insulin-Like Growth Factor I/genetics , Interleukin-2/metabolism , Jurkat Cells , Kinetics , Lectins, C-Type , Mitogen-Activated Protein Kinases/metabolism , RNA, Messenger/metabolism , Receptor, IGF Type 1/metabolism , Receptors, Interleukin-2/drug effects , Receptors, Interleukin-2/metabolism , T-Lymphocytes/immunology , Transcription, Genetic/drug effects
4.
Immunopharmacology ; 29(1): 1-10, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7768666

ABSTRACT

The anti-depressive drug trifluoperazine (TFP) was studied on in vitro immune responses. TFP proved to be an inhibitor of lymphokine-activated killer (LAK) cells in its generative step, as well as in its effector phase. Natural killer (NK) activity and interleukin-2 (IL-2) or mitogen-induced lymphocyte proliferation were just as sensitive to the drug effects, whereas the division of tumor cells was more resistant. The mechanism through which TFP suppresses these lymphocytic systems remains unclear. It does not, however, affect an early stage of cellular activation as the addition of the drug as late as 24 h after the start of the culture was still inhibitory for lymphocyte mitogenesis. Neither the expression of CD25, nor that of CD56 was affected by TFP, and exogenous IL-2 was unable to overcome the suppression of proliferation. In relation to cell-mediated cytotoxicity, TFP partially interfered with the effector/target binding. However, addition of lectin to the assay did not overcome the inhibition of lysis produced by the drug. Although further work remains to be done, the effect of TFP on immune responses must be taken into consideration when treating immunosuppressed patients.


Subject(s)
Killer Cells, Lymphokine-Activated/drug effects , Trifluoperazine/toxicity , Antigens, Differentiation, T-Lymphocyte/drug effects , Antigens, Differentiation, T-Lymphocyte/genetics , Binding, Competitive , Cell Division/drug effects , Dipeptidyl Peptidase 4/biosynthesis , Flow Cytometry , Humans , Immunosuppression Therapy , Interleukin-2/pharmacology , Killer Cells, Natural/drug effects , Leukemia, Erythroblastic, Acute/pathology , Leukemia, T-Cell/pathology , Lymphocyte Activation/drug effects , Lymphocyte Activation/genetics , Mitogens/pharmacology , Receptors, Interleukin-2/biosynthesis , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL